- Home
- EIC vs STRO Comparison
EIC vs STRO Comparison
Compare EIC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- STRO
- Stock Information
- Founded
- EIC N/A
- STRO 2003
- Country
- EIC United States
- STRO United States
- Employees
- EIC N/A
- STRO N/A
- Industry
- EIC Finance/Investors Services
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EIC Finance
- STRO Health Care
- Exchange
- EIC Nasdaq
- STRO Nasdaq
- Market Cap
- EIC 250.6M
- STRO 292.6M
- IPO Year
- EIC 2019
- STRO 2018
- Fundamental
- Price
- EIC $16.46
- STRO $4.38
- Analyst Decision
- EIC
- STRO Strong Buy
- Analyst Count
- EIC 0
- STRO 8
- Target Price
- EIC N/A
- STRO $12.13
- AVG Volume (30 Days)
- EIC 116.0K
- STRO 482.6K
- Earning Date
- EIC 11-14-2023
- STRO 11-19-2024
- Dividend Yield
- EIC 13.63%
- STRO N/A
- EPS Growth
- EIC N/A
- STRO N/A
- EPS
- EIC 0.80
- STRO N/A
- Revenue
- EIC N/A
- STRO $169,359,000.00
- Revenue This Year
- EIC N/A
- STRO N/A
- Revenue Next Year
- EIC N/A
- STRO N/A
- P/E Ratio
- EIC $20.31
- STRO N/A
- Revenue Growth
- EIC N/A
- STRO 197.83
- 52 Week Low
- EIC $13.00
- STRO $2.01
- 52 Week High
- EIC $16.48
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- EIC 61.21
- STRO 68.55
- Support Level
- EIC $15.88
- STRO $3.22
- Resistance Level
- EIC $16.30
- STRO $3.74
- Average True Range (ATR)
- EIC 0.25
- STRO 0.26
- MACD
- EIC 0.06
- STRO 0.10
- Stochastic Oscillator
- EIC 79.75
- STRO 93.55
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.